Latest Manufacturing And Supply Chain News

Cardiex Limited has announced a fully underwritten 1-for-4 entitlement offer at $0.04 per share, aiming to raise approximately $4.1 million to advance manufacturing and scale its supply chain. The offer closes on 20 June 2025, following a recent $2.4 million placement.

TruScreen Group Limited has announced a capital raising initiative involving Placement and Share Purchase Plan (SPP) Options, aiming to secure approximately NZ$3 million to fund strategic growth and working capital needs. The offer, subject to shareholder approval, includes up to 80.9 million Placement Options and 55.5 million SPP Options exercisable at A$0.02.

Clarity Pharmaceuticals has successfully imaged the first patient in its pivotal Phase III AMPLIFY trial for Cu-SAR-bisPSMA, a next-generation diagnostic agent targeting recurrent prostate cancer. This milestone sets the stage for potential FDA approval and broader clinical adoption.

Nanoveu Limited has launched a $2.7 million capital raising via a share placement and a substantial options offer, pending shareholder approval for securities issued to its Executive Chairman. The prospectus outlines key risks and the impact on the company’s capital structure.

Orica Limited reported its strongest half-year EBIT in over a decade, driven by robust demand for premium blasting products and technology adoption, alongside significant safety and sustainability achievements.

Cardiex Limited has formally lodged its CONNEQT Pulse device with Australia's Therapeutics Goods Administration, marking a critical step toward regulatory approval and market expansion.

Lode Resources has reported exceptional high-grade antimony and silver drill results from its Montezuma Project in Tasmania, alongside commencing a substantial 50-60 hole drilling program to expand the deposit.

Cleo Diagnostics reports steady progress in its U.S. and Australian clinical trials for an ovarian cancer blood test, maintaining a solid cash reserve of A$7.3 million as it prepares for FDA submission.

Clarity Pharmaceuticals reports robust progress in its SECURE trial and secures FDA Fast Track Designation for its diagnostic agent 64Cu-SAR-bisPSMA, underpinning its growth and innovation in prostate cancer treatment.